Phase 2 N=60 Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
Squamous Cell Carcinoma of Oropharynx
Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
Cervical Adenocarcinoma · Cervical Squamous Cell Carcinoma · Human Papillomavirus Infection
Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events
Phase 2 N=370 Gentamicin Intravesical Efficacy for Infection of Urinary Tract
Postoperative Urinary Tract Infection · Pelvic Organ Prolapse · Stress Urinary Incontinence
Primary: Post-operative Urinary Tract Infection — 19; 20 Participants
Phase 2 N=6 Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Change From Baseline in Summed Standardized Uptake Value (SUVmax) of Lesion After 2 Cycles of Chemotherapy — 27.45 percentage of SUV Max change
Phase 2 N=53 Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer
Breast Cancer · Joint Pain
Primary: Change in WOMAC Score — 24.9 Score on a scale — p=0.004
Phase 2 N=37 A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney, Autosomal Dominant
Primary: Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) — 24; 8; 5; 1 Participants
Phase 2 N=19 Effectiveness of an Opioid Sparing Pain Regimen in Cardiac Surgery
Pain, Postoperative
Primary: The Number of Patients With Requests for Breakthrough Opioid Pain Medication in Opioid Standard of Care Regimen Compared to Non-opioid Multimodal Pain Relief Regimen…
Phase 2 N=44 Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Liver Cancer
Primary: Progression Free Survival (PFS) — 43 months
Phase 2 N=198 Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 24; 24; 24; 24 Participants
Phase 2 N=23 Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)
Myelodysplastic Syndromes
Primary: The Number of Patients With Grade 3 or Higher Serious Adverse Events. — 3 Participants
Phase 2 N=66 Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1) — NA; NA Participants
Phase 2 N=140 A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Double-blind Treatment Period: Percent Change in Eczema Area and Severity Index (EASI) Score — -58.68; -57.18; -48.41 Percent change — p==0.1198
Phase 2 N=93 Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)
COVID-19
Primary: Composite of All-cause Mortality, Need for Mechanical Ventilation, or Need for Mechanical Circulatory Support (MCS) — 9; 6 Participants
Phase 2 N=198 Efficacy and Safety of Oral BT-11 in Ulcerative Colitis
Ulcerative Colitis
Primary: Clinical Remission — 30.3; 31.8; 22.7 percentage of participants
Phase 2 N=275 Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis (NASH)
Primary: Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) — 21…